Summary
Twenty-four women (mean age±SD 49±13 years) with classical or definite rheumatoid arthritis (disease duration 15±8 years) were treated with synthetic salmon calcitonin (SCT) nasal spray 200 IU three times a week for 3 months. Bone biopsies from the iliac crest were taken before and after SCT treatment. Histomorphometrical quantification of undecalcified bone sections was made using the manual point-counting method. SCT decreased the resorption surface of trabecular bone (ES/BS) significantly (P< 0.001). There was also a significant increase (P< 0.05) in trabecular bone volume (BV/TV) after 3 months of treatment, whereas no statistically significant changes were found in osteoid parameters. There were no significant changes in biochemical analyses of bone metabolism. We conclude that SCT might be useful in the prevention of bone loss in RA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bywaters EGL (1960) The early radiological signs of rheumatoid arthritis. Bull Rheum Dis 11:231–234
Soila P, (1963) The causal relations of rheumatoid disintegration of juxta-articular bone trabeculae. Acta Rheum Scand 9:231–236
Duncan H, Frost HM, Villaneuva AR, Sigler JW (1965) The osteoporosis of rheumatoid arthritis. Arthritis Rheum 8:943–954
Reid DM, Kennedy NSJ, Smith MA, Tothill P, Nuki G (1982) Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid therapy. Br Med J 285:330–332
Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721–728
Als OS, Gotfredsen A, Riis BJ, Christiansen C (1985) Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis 44:406–411
Friedman J, Raisz LG (1965) Thyrocalcitonin, inhibitor of bone resorption in tissue culture. Science 150:1465–1467
Singer FR, Melvin KEW, Mills BG (1976) Acute effects of calcitonin on osteoclasts in man. Clin Endocrinol 5:333–340
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp BP, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303
Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini (1986) Effect of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) 1-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet ii:1481–1483
Overgaard K, Riis BJ, Christiansen CJ, Hansen MA (1989) Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 299:477–479
Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662
Frost HM (1983) Bone histomorphometry: choice of marking agent and labeling schedule. In: Recker RR (ed) Bone histomorphometry: techniques and interpretation. CRC Press, Boca Raton, p 37
Frost HM (1969) Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 3:211–237
Parviainen MT, Savolainen KE, Korhonen PH, Alhava EM, Visakorpi JK (1981) An improved method for routine determination of vitamin D and its hydroxylated metabolites in serum from children and adults. Clin Chim Acta 114:233–247
Kröger H, Penttilä I (1990) Osteocalcin in serum of healthy Finnish women determined by radioimmunoassay—effects of menopause on its concentration. Scand J Clin Lab Invest 50(suppl 202):187
Huskisson EC (1974) Measurement of pain. Lancet ii:1127–1131
Kennedy AC, Lindsay R (1977) Bone involvement in rheumatoid arthritis. Clin Rheum Dis 3:403–420
Oka M, Rekonen A, Kuikka J, Anttinen J (1975) Bone mineral density in rheumatoid arthritis measured by the gamma transmission method. Scand J Rheumatol 4:28–32
Dequeker J, Geusens P, Verstraeten A, Sileghem A (1990) Effects of nasal calcitonin on pain, bone erosion and bone loss in rheumatoid arthritis (abstract). In: Overgaard K, Christiansen C (eds) 3rd Int Symp on Osteoporosis. Handelstrykkeriet Aalborg ApS, Aalborg, p 128
Chavassieux PM, Arlot ME, Meunier PJ (1985) Intersample variation in bone histomorphometry: comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif Tissue Int 37:345–350
Als OS, Riis BJ, Gotfredsen A, Christiansen C, Deftos LJ (1986) Biochemical markers of bone turnover in rheumatoid arthritis. Acta Med Scand 219:209–213
Gevers G, Devos P, De Roo M, Dequeker J (1986) Increased levels of osteocalcin (serum bone gla-protein) in rheumatoid arthritis. Br J Rheumatol 25:260–262
Pietschmann P, Machold KP, Wolosczuk W, Smolen JS (1989) Serum osteocalcin concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 48:654–657
MacIntyre I, Evans IMA, Hobitz HHG, Joplin GF, Stevenson JC (1980) Chemistry, physiology, and therapeutic applications of calcitonin. Arthritis Rheum 23:1139–1147
Gennari C (1983) Clinical aspects of calcitonin in pain. Triangle 22:157–163
MacIntyre I, Stevenson JC, Whitehead MJ, Wimalawansa SJ, Banks LM, Healy MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet i:900–902
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kröger, H., Arnala, I. & Alhava, E.M. Effect of calcitonin on bone histomorphometry and bone metabolism in rheumatoid arthritis. Calcif Tissue Int 50, 11–13 (1992). https://doi.org/10.1007/BF00297290
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00297290